Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 1087

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 1087
---
 |             |     |              |     |      |   |              |               |             |     |              |                    |   |     |                |     | — |     |   |       |
|                           |              |                     | 201,118,000 |     |              |     |      |   |              |               | 201,118,000 |     |              |                    | — |     |                |     | — |     |   |       |

| * | Represents beneficial ownership. |

| ** | Calculated assuming that public shareholders holding all 29,117 Denali Class A Ordinary Shares issued and outstanding and subject to redemption will exercise their redemption rights upon consummation of the Business Combination (the maximum redemption scenario). |

| *** | Less than 1%. |

| (1) | Consists of (a) 1,118,000 shares of New Semnur Common Stock held directly by Scilex, (b) 193,750,000 shares of New Semnur Common Stock held directly by Scilex, Inc., a wholly owned subsidiary of Scilex and formerly known as “Scilex Holding Company”, and (iii) 6,250,000 shares of New Semnur Common Stock held directly by Scilex Bio, Inc., a majority owned subsidiary of Scilex. As the sole owner of Scilex, Inc. and the majority owner of Scilex Bio, Inc., Scilex has the authority to direct the voting and disposition of the shares of New Semnur Common Stock held directly by each of Scilex, Inc. and Scilex Bio, Inc. The registered office of each of Scilex, Scilex, Inc. and Scilex Bio is 960 San Antonio Road, Palo Alto, CA 94303. The number of shares of New Semnur Common Stock referenced in the preceding clause (a) assumes that the Aggregate Outstanding Amount under the Debt Exchange Agreement is $60,000,000 (the maximum amount permitted thereunder), which is exchanged pursuant to the terms thereof for a maximum of 6,000,000 shares of Semnur Preferred Stock, which are in turn, at the Effective Time, exchanged for a maximum of 6,000,000 shares of New Semnur Series A Preferred Stock. If the Aggregate Outstanding Amount under the Debt Exchange Agreement is less than the maximum amount permitted thereunder, Scilex’s voting total voting power after the Offering will